Literature DB >> 1682174

Pharmacological measures to prevent post-operative urinary retention; a prospective randomized study.

C Savona-Ventura1, E S Grech, I Saliba.   

Abstract

One hundred patients undergoing vaginal surgery for genital prolapse were randomly allocated to one of four post-operative management groups which included a control group and three groups receiving differently acting pharmacological agents (distigmine bromide, phenoxybenzamine hydrochloride, and prostaglandin F2 alpha) variously reported as being useful in preventing urinary retention after vaginal surgery. The incidence of an elevated residual volume in the control group was 10.7%. All the pharmacological agents appeared to increase by about three times the incidence of an elevated residual urinary volume with statistical significance (P less than 0.05) being noted for distigmine bromide and PGF2 alpha. While this increased incidence occurred irrespective of the type of surgery in the case of distigmine bromide and phenoxybenzamine . HCl, the increase was most marked (P less than 0.01) when PGF2 alpha was used after anterior repair surgery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682174     DOI: 10.1016/0028-2243(91)90028-j

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

Review 1.  Current pharmacological and surgical treatment of underactive bladder.

Authors:  Dae Kyung Kim
Journal:  Investig Clin Urol       Date:  2017-11-17

Review 2.  Female underactive bladder - Current status and management.

Authors:  Tammer Yamany; Marlie Elia; Jason Jihoon Lee; Ajay K Singla
Journal:  Indian J Urol       Date:  2019 Jan-Mar

3.  Medical and non-medical interventions for post-operative urinary retention prevention: network meta-analysis and risk-benefit analysis.

Authors:  Pokket Sirisreetreerux; Rujira Wattanayingcharoenchai; Sasivimol Rattanasiri; Oraluck Pattanaprateep; Pawin Numthavaj; Ammarin Thakkinstian
Journal:  Ther Adv Urol       Date:  2021-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.